A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse

Clinical Immunology

Volumn 110, Issue 2, 2004, Pages 181-190

  Offner, Halina ^a,b   Zamora, Alex ^b   Subramanian, Sandhya ^b   Polanczyk, Magdalena ^b   Krogstad, Aric ^c   Auci, Dominick L ^d   Morgan, Elizabeth E ^d   Reading, Christopher L ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d Hollis Eden Pharmaceuticals Inc   (United States)

Author keywords

Androstene; Arthritis; CIA; Cytokines; DHEA

Indexed keywords

ANDROSTANE DERIVATIVE; COLLAGEN; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; FLUASTERONE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTHRITIS; ARTICLE; CATTLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; EROSION; HISTOPATHOLOGY; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVITIS;

EID: 1542330840     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2003.11.003     Document Type: Article

References (59)

1. Myers L.K., Tang B., Rosloniec E.F., Stuart J.M., Chiang T.M., Kang A.H. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J. Immunol. 161:1998;3589.
2. Taneja V., Taneja N., Paisansinsup T., Behrens M., Griffiths M., Luthra H., David C.S. CD4 and CD8 T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis. J. Immunol. 168:2002;5867.
3. Rosloniec E.F., Whittington K.B., Brand D.D., Myers L.K., Stuart J.M. Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis. Cell. Immunol. 172:1996;21.
4. Williams R.O., Feldmann M., Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U.S.A. 89:1992;9784.
5. Joosten L.A., Helsen M.M., Saxne T., van De Loo F.A., Heinegard D., van Den Berg W.B. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163:1999;5049.
6. Quattrocchi E., Walmsley M., Browne K., Williams R.O., Marinova-Mutafchieva L., Buurman W., Butler D.M., Feldmann M. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. J. Immunol. 163:1999;1000.
7. Marinova-Mutafchieva L., Williams R.O., Funa K., Maini R.N., Zvaifler N.J. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum. 46:2002;507.
8. Whitacre C.C., Reingold S.C., O'Looney P.A. A gender gap in autoimmunity. Science. 283:1999;1277.
9. Roubinian J.R., Papoian R., Talal N. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J. Clin. Invest. 59:1977;1066.
10. Makino S., Kunimoto K., Muraoka Y., Katagiri K. Effect of castration on the appearance of diabetes in NOD mouse. Jikken Dobutsu. 30:1981;137.
11. Ahmed S.A., Penhale W.J. The influence of testosterone on the development of autoimmune thyroiditis in thymectomized and irradiated rats. Clin. Exp. Immunol. 48:1982;367.
12. Allen J.B., Blatter D., Calandra G.B., Wilder R.L. Sex hormonal effects on the severity of streptococcal cell wall-induced polyarthritis in the rat. Arthritis Rheum. 26:1983;560.
13. Voskuhl R.R., Pitchekian-Halabi H., MacKenzie-Graham A., McFarland H.F., Raine C.S. Gender differences in autoimmune demyelination in the mouse: implications for multiple sclerosis. Ann. Neurol. 39:1996;724.
14. Bebo B.F. Jr., Vandenbark A.A., Offner H. Male SJL mice do not relapse after induction of EAE with PLP 139-151. J. Neurosci. Res. 45:1996;680.
15. Blazkovec A.A., Orsini M.W. Ontogenetic aspects of sexual dimorphism and the primary immune response to sheep erythrocytes in hamsters from prepuberty through senescence. Int. Arch. Allergy Appl. Immunol. 50:1976;55.
16. Oka M., Vainio U. Effect of pregnancy on the prognosis and serology of rheumatoid arthritis. Acta Rheumatol. Scand. 12:1966;47.
17. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339:1998;285.
18. Hanson G.C., Ghosh S. Systemic lupus erythematosus and pregnancy. Br. Med. J. 5472:1965;1227.
19. Ostensen M., Husby G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 26:1983;1155.
20. Wilder R.L. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. J. Rheumatol., Suppl. 44:1996;10.
21. Wilder R.L. Neuroimmunoendocrinology of the rheumatic diseases: past, present, and future. Ann. N. Y. Acad. Sci. 966:2002;13.
22. Cutolo M., Balleari E., Giusti M., Intra E., Accardo S. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum. 34:1991;1.
23. Cutolo M. Sex hormone adjuvant therapy in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 26:2000;881.
24. Miller R.A. Aging and immune function. Int. Rev. Cytol. 124:1991;187.
25. Small M., Gray C.E., Beastall G.H., MacCuish A.C. Adrenal androgens in insulin-dependent diabetes mellitus. Diabetes Res. 11:1989;93.
26. Henderson E., Schwartz A., Pashko L., Abou-Gharbia M., Swern D. Dehydroepiandrosterone and 16 alpha-bromo-epiandrosterone: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes. Carcinogenesis. 2:1981;683.
27. Khaw K.T. Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. J. Endocrinol. 150:1996;S149. Suppl.
28. van Vollenhoven R.F., Bieber M.M., Powell M.J., Gupta P.K., Bhat N.M., Richards K.L., Albano S.A., Teng N.N. VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics. J. Rheumatol. 26:1999;1727.
29. Du C., Khalil M.W., Sriram S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J. Immunol. 167:2001;7094.
30. Yen T.T., Allan J.A., Pearson D.V., Acton J.M., Greenberg M.M. Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids. 12:1977;409.
31. Ben-David M., Dikstein S., Bismuth G., Sulman F.G. Anti- hypercholesterolemic effect of dehydroepiandrosterone in rats. Proc. Soc. Exp. Biol. Med. 125:1967;1136.
32. van Vollenhoven R.F. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin. Pharmacother. 3:2002;23.
33. Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., Madhok R., Campbell C., Gracie J.A., Liew F.Y., McInnes I.B. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170:2003;1524.
34. Marwah A., Marwah P., Lardy H. Ergosteroids: VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 767:2002;285.
35. Ebeling P., Koivisto V.A. Physiological importance of dehydroepiandrosterone. Lancet. 343:1994;1479.
36. Auci D.L., Ahlem C., Li M., Trauger R., Dowding C., Paillard F., Frincke J., Reading C. The immunobiology and therapeutic potential of androstene hormones and their synthetic derivatives: novel anti-inflammatory and immune regulating steroid hormones. Mod. Asp. Immunobiol. 12:2003;312.
37. Schwartz A.G., Pashko L.L. Inhibition of adjuvant-induced arthritis by 16 alpha-fluoro-5-androsten-17-one. Mil. Med. 167:2002;60.
38. Offner H., Zamora A., Drought H., Matejuk A., Auci D., Morgan E., Vandenbark A., Reading C. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. J. Neuroimmunol. 130:2002;128.
39. Kanik K.S., Wilder R.L. Hormonal alterations in rheumatoid arthritis, including the effects of pregnancy. Rheum. Dis. Clin. North Am. 26:2000;805.
40. Kanik K.S., Chrousos G.P., Schumacher H.R., Crane M.L., Yarboro C.H., Wilder R.L. Adrenocorticotropin, glucocorticoid, and androgen secretion in patients with new onset synovitis/rheumatoid arthritis: relations with indices of inflammation. J. Clin. Endocrinol. Metab. 85:2000;1461.
41. Bebo B.F. Jr., Schuster J.C., Vandenbark A.A., Offner H. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J. Immunol. 162:1999;35.
42. Bebo B.F. Jr., Fyfe-Johnson A., Adlard K., Beam A.G., Vandenbark A.A., Offner H. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J. Immunol. 166:2001;2080.
43. Latham B.P., Zamora A., Drought H., Subramanian S., Matejuk A., Offner H., Rosloniec E.P. Estradiol treatment redirects the isotype of the autoantibody response and prevents the development of autoimmune arthritis. J. Immunol. 171:2003;5820.
44. Ito A., Bebo B.F. Jr., Matejuk A., Zamora A., Silverman M., Fyfe-Johnson A., Offner H. Estrogen treatment down-regulates TNF-alpha production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J. Immunol. 167:2001;542.
45. Ye X.J., Marion T.N., Terato K., Aelion J.A., Cremer M.A., Tillman D.M., Krug M.S., Jackson B., Yoo T.J. Variable-region gene family usage for type II collagen autoantibodies in arthritis-susceptible DBA/1 mice. Clin. Immunol. Immunopathol. 78:1996;263.
46. Brand D.D., Kang A.H., Rosloniec E.F. Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol. 25:2003;3.
47. Zhou Y.C., Waxman D.J. Activation of peroxisome proliferator-activated receptors by chlorinated hydrocarbons and endogenous steroids. Environ. Health Perspect. 106(Suppl. 4):1998;983.
48. Peters J.M., Zhou Y.C., Ram P.A., Lee S.S., Gonzalez F.J., Waxman D.J. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol. Pharmacol. 50:1996;67.
49. Spiegelman B.M., Flier J.S. Adipogenesis and obesity: rounding out the big picture. Cell. 87:1996;377.
50. Forman B.M. The PPARs 2001: it's not over 'til the fat lady sings. Trends Mol. Med. 7:2001;331.
51. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science. 294:2001;1866.
52. Delerive P., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169:2001;453.
53. Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., Fruchart J.C., Chapman J., Najib J., Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273:1998;25573.
54. Daynes R.A., Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev., Immunol. 2:2002;748.
55. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:1998;79.
56. Schwartz A.G., Pashko L., Whitcomb J.M. Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol. Pathol. 14:1986;357.
57. Perkins S.N., Hursting S.D., Haines D.C., James S.J., Miller B.J., Phang J.M. Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis. 18:1997;989.
58. Ciolino H.P., Yeh G.C. The effects of resveratrol on CYP1A1 expression and aryl hydrocarbon receptor function in vitro. Adv. Exp. Med. Biol. 492:2001;183.
59. Liu D., Dillon J.S. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J. Biol. Chem. 277:2002;21379.